Panel pans FDG-PET evidence for expanded Medicare coverage

August 20, 2008 Panel pans FDG-PET evidence for expanded Medicare coverage H. A. Abella ------------------------------------------------------------------------------- A Centers for Medicare and Medicaid Services advisory panel has found that most available clinical data for nine conditionally approved cancer indications of FDG-PET, evaluated by the National Oncologic PET Registry and a separate Canadian study, are too ambivalent to support Medicare coverage. The nine-member Medicare Evidence Development and Coverage Advisory Committee (MedCAC) heard testimony from the Evidence-Based Practice Center in Edmonton, AB, and the NOPR on Aug. 20 in Woodland, MD. Members of the American College of Radiology, American Society for Therapeutic Radiology and Oncology, Academy of Molecular Imaging, and SNM, as well as patient advocates, also testified.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC